Search Results

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan, announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

The agreement will give Kura enough capital to support the development and launch of its menin inhibitor ziftomenib.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will share new research that advances understanding about the real-world experiences and clinical characteristics of children, adolescents, and adults living with X-linked hypophosphatemia (XLH), a rare genetic metabolic bone disease.

Kyowa Kirin, Inc. will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ® (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson’s Disease (PD).